rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Dare Bioscience, Inc.

DARE · Nasdaq

Health CareBiotechnologyNot moving yet

DARE stood above a rising 150-day average in 10 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 54.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 14
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
24 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 10 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders24+1 on the quarter
New · exited5 · 4
Reported value$2.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026640,877$1.4M+178,572+38.6%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026140,093$296K-37,746−21.2%
US BANCORP \DE\added · filed 12 Aug 2026120,920$255K+29,550+32.3%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202691,269$193K+25,331+38.4%
BlackRock, Inc.added · filed 7 Aug 202664,248$136K+47,277+278.6%
STATE STREET CORPadded · filed 7 Aug 202647,415$100K+23,900+101.6%
JANE STREET GROUP, LLCnew · filed 14 Aug 202636,092$76K+36,092
NORTHERN TRUST CORPadded · filed 13 Aug 202634,209$72K+18,778+121.7%
LPL Financial LLCadded · filed 7 Aug 202614,889$31K+250+1.7%
RAYMOND JAMES FINANCIAL INCreduced · filed 14 Aug 202614,864$31K-470−3.1%
30 Jun 2024 – 30 Jun 2026
41423Jun 24Dec 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Gregory W. Matz Company insiderDirector · last 30 Jun 20260 · 0
Jessica D. Grossman Company insiderDirector · last 30 Jun 20260 · 0
Robin Joan Steele Company insiderDirector · last 30 Jun 20260 · 0
Susan L. Kelley Company insiderDirector · last 30 Jun 20260 · 0
William H. Rastetter Company insiderDirector · last 30 Jun 20261 · 0
Sabrina Martucci Johnson Company insiderChef Executive Officer · last 18 Feb 20260 · 0
MarDee Haring-Layton Company insiderChief Accounting Officer · last 30 Jan 20260 · 0
John A. Fair Company insiderChief Commercial Officer · last 12 Mar 20240 · 0
Cheryl R. Blanchard Company insiderDirector · last 21 Jun 20230 · 0
Sophia Nnenna Ononye-Onyia Company insiderDirector · last 21 Jun 20230 · 0
Lisa Walters-Hoffert Company insiderChief Financial Officer · last 24 Jan 20230 · 0
Roger Hawley Company insiderDirector · last 13 Jun 20192 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202571.3%
Free cash flow marginFY 2025 · to 31 Dec 2025-997%
Return on capital employedFY 2025 · to 31 Dec 2025-154%
Share count trendFY 2025 · to 25 Mar 20260.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$24.7M
Free cash flowFY 2025 · to 31 Dec 2025−$10.3M

Analyst forecasts

No analyst forecasts yet.